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Abstract
Background: Heptavalent pneumococcal conjugate vaccine (PCV7) shifts nasopharyngeal colonisation with vaccine
serotype pneumococci towards nonvaccine serotypes. Because of the reported negative association of vaccine serotype
pneumococci and Staphylococcus aureus in the nasopharynx, we explored the effect of PCV7 on nasopharyngeal
colonisation with S. aureus in children and parents.
Methodology/Principal Findings: This study was part of a randomised controlled trial on the effect of PCV7 on
pneumococcal carriage, enrolling healthy newborns who were randomly assigned (1:1:1) to receive PCV7 (1) at 2 and 4
months of age (2) at 2, 4 and 11 months or (3) no PCV7 (controls). Nasopharyngeal colonisation of S. aureus was a planned
secondary outcome. Nasopharyngeal swabs were obtained from all children over a 2-year period with 6-months interval and
from one parent at the child’s age of 12 and 24 months and cultured for Streptococcus pneumoniae and S. aureus. Between
July 2005 and February 2006, 1005 children were enrolled and received either 2-doses of PCV7 (n = 336), 2+1-doses (336) or
no dose (n = 333) before PCV7 implementation in the Dutch national immunization program. S. aureus colonisation had
doubled in children in the 2+1-dose group at 12 months of age compared with unvaccinated controls (10.1% versus 5.0%;
p = 0.019). A negative association for co-colonisation of S. pneumoniae and S. aureus was observed for both vaccine serotype
(adjusted odds ratio (aOR) 0.53, 95% confidence interval (CI) 0.38–0.74) and nonvaccine serotype pneumococci (aOR 0.67,
95% CI 0.52–0.88).
Conclusions/Significance: PCV7 induces a temporary increase in S. aureus colonisation in children around 12 months of age
after a 2+1-dose PCV7 schedule. The potential clinical consequences are unknown and monitoring is warranted.
Trial Registration: ClinicalTrials.gov NCT00189020
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Introduction
Seven-valent CRM197-conjugated pneumococcal vaccine (PCV7)
provides protection against vaccine serotype invasive pneumococcal
disease (IPD) [1], pneumonia and acute otitis media in young
children [2]. In the nasopharynx, PCV7 reduces colonisation with
vaccine serotype pneumococci [3–5] and due to herd effects
nasopharyngeal carriage of pneumococcal vaccine serotypes in
children has virtually disappeared several years after widespread
infant PCV7 vaccination [6]. The vacant ecological niche in the
nasopharynx seems immediately occupied by nonvaccine serotype
pneumococci resulting in a shift in serotype carriage with limited to
no net reduction in overall pneumococcal carriage [3,4,5,7].
S. pneumoniae is a frequent coloniser in the dynamic nasopha-
ryngeal milieu interieure and pneumococcal serotype shifts following
PCV7 vaccination may affect other bacteria present in the
nasopharynx. For example, several studies found a negative
association between the presence of S. aureus and PCV7 vaccine
serotype pneumococci in the nasopharynx in unvaccinated
children [8–10]. This may imply an upcoming presence of S.
aureus after PCV7-vaccinations. A higher staphylococcal nasal load
has been suggested to lead to higher dispersal to other extra-nasal
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sites harbouring S. aureus like the nasopharynx. Furthermore, S.
aureus colonisation is associated with a higher risk of infection [11].
S. aureus is an important cause of respiratory tract infections such as
chronic recurrent otitis media and pneumonia, skin infections and
community-acquired bloodstream infections in particular in
children under 5 years of age, with increasing prevalence of multi
resistant strains [12].
Investigating the effect of PCV7 on nasopharyngeal presence of
bacteria that may behave as disease pathogens is relevant. As part
of a longitudinal randomised controlled trial on the effects of a 2-
dose and 2+1-dose PCV7-schedule on nasopharyngeal pneumo-
coccal colonisation during the first two years of life, we assessed the
effects of PCV7 on S. aureus colonisation in children and parents as
secondary outcomes.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1, Protocol
S1 and Summary Protocol S1.
Participants and Ethics Statement
This was a randomized controlled study including healthy
newborns from the western part of The Netherlands. The trial
methodology and results for pneumococcal carriage efficacy have
been published previously [5,13]. Written informed consent was
obtained from both parents or guardian. This study received
approval by an acknowledged national ethics committee (Stichting
Therapeutische Evaluatie Geneesmiddelen) from the Netherlands
and was undertaken in accordance with the European Statements
for Good Clinical Practice, which includes the provisions of the
Declaration of Helsinki. Participants did not receive any financial
compensation.
Randomization and Blinding
Infants were randomly allocated (1:1:1) to receive (1) PCV7 at
the age of 2 and 4 months (2-dose group); (2) PCV7 at 2, 4, and 11
months (2+1-dose group); or (3) no PCV7 (unvaccinated control
group). Randomisation was performed during the first home-visit
via a computer-randomisation interface. The assigned vaccination
schedule was communicated with the well baby clinic where
vaccinations were administered. The study nurses and parents
were unmasked to the intervention assignment but the outcome
assessors were blinded throughout the study and the randomisa-
tion key was not disclosed until after the study.
Procedures
Deep nasopharyngeal swabs were taken transnasally by trained
study nurses according to WHO standard procedures [14] during
home visits at age 6 weeks and at age 6, 12, 18 and 24 months and
from parents at the child’s age of 12 and 24 months. From parents,
also a transoral nasopharyngeal swab was collected, as the
pneumococcal yield is known to be higher in adults when taking
both swabs [15]. Transoral swabs were taken under direct
observation of the posterior pharynx with a rigid cotton-wool
swab. After sampling, swabs were immediately inoculated in
Transwab (modified Amies) transport medium and stored at room
temperature. Swabs were plated within 24 hours onto two 5%
sheep blood agar plates, 1 with 5 mg/L gentamicin and 1 without.
Agar plates were incubated at 35uC for 48 hours (the gentamicin
plate with raised CO2). Isolates were identified using colony
morphology and conventional methods of determination. Sero-
typing of S. pneumoniae was performed by capsular swelling method
(Quellung reaction) using type-specific antisera from the Statens
Seruminstitut (Copenhagen, Denmark). A questionnaire on risk
factors for nasopharyngeal bacterial colonisation was obtained
with each nasopharyngeal swab.
Sample Size and Statistical Methods
Sample size calculation for the trial was based on the main
outcome measure of the study, vaccine serotype pneumococcal
carriage in the second year of life, resulting in a sample size of 330
infants per group including a 10% dropout rate as previously
described [5]. The present analyses were planned as secondary
outcomes. All statistical analyses in the trial were carried out
according to the intention-to-treat principle, meaning that all
available data from all randomized participants were analyzed
according to the assigned intervention. Parents of twins were
excluded from the analyses. Because the dropout rate (,2%) and
the amount of missing data (,2%) were low, available data were
analyzed without using imputation methods. We used a repeated
measurements model taking more than one measurement per
child into account using generalized linear models procedure in
SPSS version 17.0 (SPSS Inc, Chicago, Illinois) with S. aureus
colonisation as the dependent variable and age as within-subject
variable with an unstructured correlation structure [16]. Next to
the assigned vaccination schedule (no PCV7, 2-dose, or 2+1-dose),
potential risk factors for S. aureus colonisation as identified in recent
studies were included in the model: day care attendance (no/yes),
presence of siblings (no/yes), sex (male/female), presence of S.
pneumoniae (no carrier, vaccine type, or nonvaccine type carrier)
[9,10]. Data from all infants from age 6 months up to 24 months
were included in the model. Furthermore, a multivariate logistic
regression model was constructed for each sampling moment with
S. aureus colonisation as the dependent variable and aforemen-
tioned covariates to explore possible changes over time. P-values
smaller than 0.05 were considered significant and all reported p-
values are 2-sided. The trial is registered with the ClinicalTrials.gov,
number NCT00189020.
Results
As reported previously [5,13], 1005 infants were enrolled between
July 7, 2005 and February 9, 2006, well before the introduction of
PCV7 in the Dutch national immunization program for infants who
were born after March 31 2006 in a 3+1-dose schedule without
catch-up campaign [17]. In the control group, 333 children in were
enrolled and 336 children in both the 2-dose and 2+1-dose group.
Two children were excluded after randomisation because one of the
parental approval signatures could not be obtained. The study ended
when the last child had reached 24 months of age at February 14,
2008. There were no major differences in demographics or
distribution of risk factors (e.g. number of siblings, day care
attendance) between the 3 study groups [5].
S. aureus colonisation in unvaccinated control children
and their parents
In unvaccinated children in the control group, S. aureus
colonisation was 49.1% at 6 weeks (95% confidence interval (CI),
43.7%–54.5%) and declined towards 5.0% (95% CI, 3.1%–8.0%)
from 12 months and onwards. As reported previously, pneumo-
coccal carriage increased from 15.2% (95% CI 11.7%–19.4%) at
age 6 weeks to 67.1% (95%CI 61.8%–72.0%) at age 12 months and
remained stable hereafter [5]. (Figure 1) In parents of unvaccinated
control children, the colonisation rate for S. aureus at the child’s age
of 12 months was 28.9% (95% CI 24.1%–34.2%) and 16.9% (95%
CI 13.1%–21.6%) at the child’s age of 24 months.
PCV7 on Staphylococcus aureus Colonisation
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Effect of PCV7 on S. aureus colonisation
A trend toward higher colonisation of S. aureus after PCV7
vaccination in the first 2 years of life was observed, though not
significant overall (overall significance test of model effects:
p = 0.097). However, when analyzing different time points to
investigate temporary effects of the different vaccination schedules,
S. aureus carriage was found doubled at 12 months in children in
the 2+1-dose group, 1 month after receiving the booster dose
(10.1%, 95% CI 7.4%–13.8%) compared to controls (5.0%, 95%
CI 3.1%–8.0%; p= 0.019).(Figure 2) The point estimate for S.
aureus nasopharyngeal presence in children in the 2-dose group
without the booster at 11 months was in between controls and the
group that had received the booster dose (7.5%, 95% CI 5.1%–
10.8%). At 18 and 24 months, point estimates for S. aureus carriage
were still higher in vaccinated children of both vaccine groups
compared to controls; however with low carriage rates these
differences were no longer significant. In parents, point estimates
for nasopharyngeal presence of S. aureus did not significantly differ
between the three groups at the child’s age of 12 and 24 months,
although the point estimate in parents of the 2+1-dose group
(25.5%, 95% CI 21.1%–30.6%) was higher than in parents of
children in the 2-dose group (20.4%, 95% CI 16.3%–25.2%) and
control group (20.3%, 95% CI 16.1%–25.2%) at the child’s age of
24 months. In all three groups, point estimates for S. aureus
colonisation at the child’s age of 24 months were lower compared
to at age 12 months. (Table 1)
Co-colonisation for S. aureus and S. pneumoniae
S. aureus colonisation was higher in non-pneumococcal carriers
compared to pneumococcal carriers at all sampling moments.
Analyzing the overall presence of co-colonisation for S. aureus and
S. pneumoniae during follow-up between 6 months and 24 months of
age, a negative association for both vaccine serotype (aOR 0.53,
95% CI 0.38–0.74) and to a lesser extent nonvaccine serotype
pneumococci (aOR 0.67, 95% CI 0.51–0.88) was noted.
Furthermore, day care attendance and siblings in the household
and increasing age were all negatively associated with S. aureus
colonisation.(Table 2) In multivariate logistic regression models for
each different sampling moment at different ages and adjusting for
PCV7 vaccination schedule, day care attendance, presence of
siblings and sex, colonisation with vaccine serotype pneumococci
and nonvaccine serotype pneumococci in general appeared
negatively associated with S. aureus presence though point estimates
varied slightly in time.(Table 3) In parents, no significant negative
associations between S. pneumoniae and S. aureus were observed. At
the child’s age of 12 months, S. aureus colonisation in parents
carrying pneumococci was 23.4% (95% CI 18.4%–29.2%) and in
non-pneumococcal carriers 29.8% (95% CI 26.5%–33.2%). At the
child’s age of 24 months, S. aureus colonisation was 20.7% (95% CI
15.4%–27.1%) in pneumococcal carriers and 22.5% (95% CI
19.6%–24.6%) in non-pneumococcal carriers.
Discussion
We describe for the first time a randomized, controlled
longitudinal trial exploring the effect of PCV7 on nasopharyngeal
S. aureus colonisation. We found, even after a reduced primary
dose PCV7-schedule with 2 instead of 3 primary vaccinations
before the age of 6 months, a temporary but distinct 2-fold
increase in S. aureus nasopharyngeal colonisation in PCV7
vaccinated infants at 12 months of age shortly after receiving a
booster dose. This means that for every 20 children vaccinated
with PCV7, 1 extra child is colonised with S. aureus in the
nasopharynx. Also a negative association for both vaccine serotype
pneumococci and to a lesser extent nonvaccine serotype
pneumococci and S. aureus was observed in children but not in
parents. Increased S. aureus colonisation at a vulnerable age may
have clinical consequences.
Figure 1. S. pneumoniae and S aureus colonisation in PCV7-unvaccinated control children in The Netherlands. PCV7 indicates 7-valent
pneumococcal conjugate vaccine; wks – weeks; m – months.
doi:10.1371/journal.pone.0020229.g001
PCV7 on Staphylococcus aureus Colonisation
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The observed temporary increase in S. aureus coincides with the
previously reported strong decline in vaccine serotype pneumo-
coccal carriage at the age of 12 months, one month after the
administration of the booster dose [5]. Two clinical studies, one in
otitis media patients and one in primary care visiting children, did
not observe an effect of PCV7 on S. aureus nasopharyngeal
colonisation [18,19]. However, these were both cross-sectional
studies in children of varying age (6 months to 7 years) and thus a
temporary effect related to the vaccination scheme may have easily
been missed [20]. Furthermore, these studies were performed in a
PCV7 vaccinated population with established herd effects which
means less dynamic changes after vaccination since circulation and
carriage of vaccine serotypes was already low. No effect of a 3-
primary dose schedule with 9-valent pneumococcal conjugate
vaccine in infancy on S. aureus colonisation was observed in a
colonisation study in children that participated in a randomized,
controlled trial [21]. However, this concerned a long-term follow-
up study in children at the age of 5 years. We observed only a
temporary significant effect particularly around the child’s first
birthday and shortly after the booster vaccination when the largest
changes in carriage from vaccine to nonvaccine serotypes
occurred, although point estimates for S. aureus were higher in
vaccinated children compared to unvaccinated children through-
out the second year of life. The fact that the increase in S. aureus
colonisation was no longer significant at 18 months or later may
well be due to underpowering of the study with respect to S. aureus
colonisation rates, since these are much lower compared to S.
pneumoniae rates in the second year of life.
Figure 2. Effect of PCV7 on nasopharyngeal S aureus colonisation in children. PCV7 indicates 7-valent pneumococcal conjugate vaccine;
wks – weeks; m – months * P,0.05 versus control group using Generalised Estimating Equations-model.
doi:10.1371/journal.pone.0020229.g002
Table 1. Nasopharyngeal colonisation of S. pneumoniae and S. aureus in parents of unvaccinated children and of children
receiving a 2-dose or 2+1-dose PCV7-schedule.
Parents of unvaccinated control children
Parents of children with a
2-dose PCV7-schedule
Parents of children with a 2+1-
dose PCV7-schedule
n % 95% CI n % 95% CI n % 95% CI
S. pneumoniae
Age 12 moa 84 27.5% 22.7%–32.7% 74 23.3% 18.9%–28.1% 75 22.9% 18.6%–27.6%
Age 24 mob 50 16.9% 12.9%–21.5% 63 20.4% 16.2%–25.2% 71 22.1% 17.8%–26.9%
S. aureus
Age 12 moa 88 28.9% 24.0%–34.1% 91 28.6% 23.8%–33.8% 90 27.4% 22.8%–32.5%
Age 24 mob 60 20.3% 16.0%–25.1% 63 20.4% 16.2%–25.2% 82 25.5% 21.0%–30.5%
Parents of twins (n = 15 pairs) were excluded. Analyses were performed with Chi-square or 2-sided Fisher Exact test where appropriate.
afor the control group: n = 305; for the 2-dose group: n = 318; for the 2+1-dose group: n = 328.
bfor the control group: n = 296; for the 2-dose group: n = 309; for the 2+1-dose group: n = 321.
doi:10.1371/journal.pone.0020229.t001
PCV7 on Staphylococcus aureus Colonisation
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The demonstrated negative association between S. pneumoniae, in
particular vaccine serotypes and S. aureus is in line with several
previous ecological studies that reported such a negative association
[8–10]. However, we now also found a negative association for
nonvaccine serotype pneumococci and S. aureus, albeit less strong, in
contrast to a previous Dutch study in 3097 unvaccinated children
aged 1 to 19 years before PCV7 implementation in the national
immunisation program in the Netherlands [8]. This may be due to
differences between both studies in the nonvaccine serotype pool,
either due to age differences or as a result of pneumococcal serotype
replacement in our study. In our study, we saw no association
between presence of S. aureus and pneumococci in parents, which is
in line with a previous study in adults [9]. S. aureus colonisation
dynamics in children are different from adults, with frequent
intermittent colonisation with different strains in children as
opposed to persistent colonisation in adults [22]. Next to bacterial
potential interference between S. pneumoniae and S. aureus in infants
[23–25], the presence of other bacteria that together compose the
nasopharyngeal microbiome in adults differs from in children and
this may affect interactions. Also, the adult anatomy of the nose may
influence interactions between S. aureus that has its primary niche in
the anterior nares and S. pneumoniae in the nasopharynx. Last, the
influence of mature immunity in adults may affect this interaction.
For instance, in HIV-1-positive hospitalized children, no association
between S. aureus and S. pneumoniae was observed [10].
Day care attendance, presence of siblings in the household and
increasing age, all well-known risk factors for S. pneumoniae
acquisition, were negatively associated with S. aureus colonisation.
A recent study by Regev-Yochay et al. suggested that the inverse
relation between pneumococci and S. aureus might not be
associated with the pneumococcal capsule per se and that other
characteristics such as pneumococcal pilus formation may play a
role [26]. Also, in vitro and in vivo studies have demonstrated that
the interference between the 2 pathogens may be related to
hydrogen peroxide production by S. pneumoniae, which is
bactericidal to S. aureus [23,24], through lethal induction of
resident prophages and subsequent lysogeny [25]. Furthermore,
we need to be aware that S. pneumoniae is just one of many
inhabitants of the dynamic nasopharyngeal niche and interactions
may be more complex and may involve other bacteria and/or
viruses as well. Understanding the underlying pathophysiological
mechanism for the observed interaction requires further investi-
gation of the nasopharyngeal microbiome.
Table 2. Risk factors for S. aureus colonisation in children
between 6 and 24 months of age using a Generalized
Estimating Equations-model.







12 months 0.27 0.15–0.48
18 months 0.22 0.12–0.41
24 months 0.32 0.19–0.55
Day care attendance 0.53 0.41–0.69
Siblings present in household 0.75 0.57–0.97
Female sex 0.86 0.67–1.10
S. pneumoniae colonisation
No carrier Reference
Vaccine type carrier 0.53 0.38–0.74
Nonvaccine type carrier 0.67 0.52–0.88
OR – Odds ratio; CI – Confidence interval; PCV7 – 7-valent pneumococcal
conjugate vaccine.
aCalculated using a Generalized Estimating Equations model with S. aureus
colonisation as dependent variable and age as within-subject variable with un
unstructured correlation structure. Data from all infants at age 6, 12, 18 and 24
months were included in the model; data from age 6 weeks were excluded
since day care attendance was not present at this age.
doi:10.1371/journal.pone.0020229.t002
Table 3. Distribution and odds ratios of colonisation with S. aureus adjusted for co-colonisation with S. pneumoniae and other risk
factors.
S. pneumoniae negative S. pneumoniae positive
Nonvaccine types Vaccine types
S. aureus positive n/N % n/N % aOR (95% CI)a n/N %
aOR (95%
CI)a
6 weeksa 435/829 52.5% 43/115 37.4% 0.58 (0.38–0.88) 24/58 41.4% 0.68 (0.39–
1.19)
6 monthsb 108/493 21.9% 40/285 14.0% 0.62 (0.41–0.94) 23/213 10.8% 0.47 (0.28–
0.77)
12 monthsb 41/373 11.0% 20/343 5.8% 0.68 (0.38–1.22) 14/271 5.2% 0.70 (0.36–
1.37)
18 monthsb 33/365 9.0% 16/359 4.5% 0.55 (0.29–1.05) 7/249 2.8% 0.36 (0.15–
0.86)
24 monthsb 42/403 10.4% 21/373 5.6% 0.72 (0.40–1.27) 7/210 3.3% 0.43 (0.18–
0.99)
aCalculated using a multivariate logistic regression model also including PCV7 vaccination schedule (none, 2-dose, 2+1-dose PCV7 schedule), presence of siblings in the
household (no/yes), and sex (male/female).
bCalculated using a multivariate logistic regression model also including PCV7 vaccination schedule (none, 2-dose, 2+1-dose PCV7 schedule), day care attendance (no/
yes), presence of siblings in the household (no/yes), and sex (male/female).
doi:10.1371/journal.pone.0020229.t003
PCV7 on Staphylococcus aureus Colonisation
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The consequences of the observed temporary increase in S.
aureus colonisation need further evaluation since an increased risk
of (nosocomial) S. aureus infection has been shown in S. aureus
carriers [11]. Also, a previous randomized controlled study in
children with a history of recurrent otitis media by our group
showed an increase of S. aureus in middle-ear fluids of children with
otitis after receiving pneumococcal vaccinations [27]. In this study,
PCV7 conjugate vaccinations followed by a 23-valent polysaccha-
ride booster vaccination induced a firm decline in PCV7 serotype
nasopharyngeal carriage and replacement by nonvaccine serotypes
[28]. Since the collection of middle ear fluid in this study was
restricted to the first otitis media episode after the booster
vaccination and the time interval between this vaccination and
recurrence of otitis media was relatively short, these data match
our present finding of a temporary increase in S. aureus carriage
directly following the booster dose.
With respect to surveillance of invasive S. aureus disease, no
substantial increase has been reported so far. A recent study on
paediatric community-acquired bacteremia in children aged 0 to
15 years between 2001 and 2008 in Paris, France, where PCV7
was implemented in 2002 for infants under 2 years of age but with
low uptake until 2005, reported no increase in S. aureus bacteremia
in this period [29]. In the United Kingdom, where PCV7 was
implemented in the national immunisation program in September
2006 with a catch-up campaign for children up to the age of 2
years, a similar study covering the period 1998 to 2007 showed a
small increase in S. aureus bacteremia in infants aged 1 to 11
months in 2007 but a decrease in older children [30]. However,
surveillance studies for severe staphylococcal infections in children
for a longer period after widespread PCV-implementation are
mandatory to observe the full impact on S. aureus epidemiology,
particularly in the current era with multi resistant S. aureus strains
and the introduction of broader coverage conjugate vaccines.
The prevalence of S. aureus colonisation in parents of both
vaccinated and unvaccinated children was considerably higher
than in children. The course of S. aureus colonisation, with high
colonisation rates in infancy rapidly decreasing in childhood but
again increasing towards adulthood, suggests that acquired
immunity cannot fully explain the dynamics in S. aureus [8,31].
Environmental factors, such as close contact between parents and
young infants may explain the high S. aureus rates in young infancy
[31]. Remarkably, S. aureus colonisation rates in parents decreased
between the child’s age of 12 and 24 months as well as rates for S.
pneumoniae. The colonisation rates of parents at the child’s age of 24
months, in particular that of unvaccinated children, resemble
more the lower carriage rates previously found in young adult
general population [8]. The route of transmission either from child
to parent or vice versa cannot be distinguished from our data. A
recent study by Regev-Yochay et al. demonstrated a strong
association between child and parental S. aureus colonisation with
the most likely route of transmission in their study from parent to
child [32]. Our data rather suggest that some transmission from
child to parent also occurs, in particular during the first years of
life with high mutual exposure via close contact. The higher
pneumococcal and S. aureus carriage rates in parents of vaccinated
children compared to unvaccinated children reflect the increased
dynamics of these bacteria after PCV7 vaccination in children in
the second year of life [5].
Some limitations of our study should be recognized. First, this
study was hypothesis driven. We did not correct for multiple
testing and therefore results must be interpreted with caution.
Furthermore, the rates for S. aureus in our study are low compared
to several other studies [9,22,32]. This is likely related to the
chosen sampling procedure for this replacement study, taking a
nasopharyngeal swab from the posterior nasopharynx and not a
separate nasal swab from the anterior nares, the ecological site for
S. aureus [33]. The nasopharyngeal presence of S. aureus in our
study was quite similar to that found by Cohen and colleagues who
also only obtained a nasopharyngeal swab in children with otitis
media [18]. Nevertheless, the applied method in our study was
similar for all 3 groups and therefore the observed differences in S.
aureus presence between vaccinees and controls are valid. Last, the
full 4-dose schedule comprising 3 primary doses and a booster
dose may have additional effect on shifts in nasopharyngeal
colonisation compared with our study that evaluated the effects of
reduced-dose schedules. Major strength of our study is the
randomized, controlled and longitudinal study design in a
PCV7-unvaccinated community in the absence of herd effects
and with relatively low bacterial antibiotic resistance rates and
therefore truly evaluating vaccine effects [34]. The effects of
nationwide PCV-introduction and subsequent herd effects on S.
aureus colonisation in young children need further monitoring.
In conclusion, we observed a temporary increase in S. aureus
colonisation after PCV7 in young children still at a vulnerable age
for bacterial infections. Widespread routine infant PCV7 vacci-
nation may cause, apart from pneumococcal serotype shifts, other
shifts in nasopharyngeal bacterial colonisation in the population.
This may especially be relevant after implementation of new
broader coverage vaccines, like the recently licensed 10-valent and
13-valent PCV’s, and/or widespread implementation of the full 4-
dose schedule which may induce more outspoken shifts in the
nasopharyngeal flora compared with our study. The potential
clinical consequences of the observed shifts in S. aureus colonisation
are unknown and further evaluation and clinical surveillance is
needed, particularly in the current era with multi resistant strains.
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